Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 554

1.

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma.

Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, Jen J, Sonneveld P, Kumar S, Kuehl WM, Rajkumar V, Van Ness B.

Blood Cancer J. 2017 Jun 30;7(6):e581. doi: 10.1038/bcj.2017.56.

2.

In vitro assembly of the Rous Sarcoma Virus capsid protein into hexamer tubes at physiological temperature.

Jaballah SA, Bailey GD, Desfosses A, Hyun J, Mitra AK, Kingston RL.

Sci Rep. 2017 Jun 6;7(1):2913. doi: 10.1038/s41598-017-02060-0.

3.

Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery.

Mandal A, Cholkar K, Khurana V, Shah A, Agrahari V, Bisht R, Pal D, Mitra AK.

Mol Pharm. 2017 Jun 5;14(6):2056-2069. doi: 10.1021/acs.molpharmaceut.7b00128. Epub 2017 May 17.

PMID:
28471177
4.

Constrained Photophysics of 5,7-dimethoxy-2,3,4,9-tetrahydro-1H-carbazol-1-one in the Bioenvironment of Serum Albumins: A Spectroscopic Endeavour Supported by Molecular Docking Analysis.

Mitra AK, Sau A, Pal U, Saha C, Basu S.

J Fluoresc. 2017 Jul;27(4):1547-1558. doi: 10.1007/s10895-017-2094-2. Epub 2017 Apr 22.

PMID:
28434063
5.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG.

Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.

6.

A de novo splice site mutation in EHMT1 resulting in Kleefstra syndrome with pharmacogenomics screening and behavior therapy for regressive behaviors.

Mitra AK, Dodge J, Van Ness J, Sokeye I, Van Ness B.

Mol Genet Genomic Med. 2016 Dec 26;5(2):130-140. doi: 10.1002/mgg3.265. eCollection 2017 Mar.

7.

Inner ear targeted drug delivery: what does the future hold?

Agrahari V, Agrahari V, Mitra AK.

Ther Deliv. 2017 Apr;8(4):179-184. doi: 10.4155/tde-2017-0001. No abstract available.

PMID:
28222657
8.

Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.

Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E, Piccirilli JA.

Cancer Res. 2017 Apr 1;77(7):1684-1696. doi: 10.1158/0008-5472.CAN-16-1454. Epub 2017 Feb 15.

PMID:
28202518
9.

Clear, Aqueous Topical Drop of Triamcinolone Acetonide.

Trinh HM, Cholkar K, Joseph M, Yang X, Mitra AK.

AAPS PharmSciTech. 2017 Feb 9. doi: 10.1208/s12249-017-0714-4. [Epub ahead of print]

PMID:
28185211
10.

Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.

Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK.

Gynecol Oncol. 2017 Mar;144(3):598-606. doi: 10.1016/j.ygyno.2017.01.015. Epub 2017 Jan 19.

PMID:
28111004
11.

Structural Model of the Tubular Assembly of the Rous Sarcoma Virus Capsid Protein.

Jeon J, Qiao X, Hung I, Mitra AK, Desfosses A, Huang D, Gor'kov PL, Craven RC, Kingston RL, Gan Z, Zhu F, Chen B.

J Am Chem Soc. 2017 Feb 8;139(5):2006-2013. doi: 10.1021/jacs.6b11939. Epub 2017 Jan 27.

PMID:
28094514
12.

Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.

Mandal A, Bisht R, Rupenthal ID, Mitra AK.

J Control Release. 2017 Feb 28;248:96-116. doi: 10.1016/j.jconrel.2017.01.012. Epub 2017 Jan 11. Review.

PMID:
28087407
13.

How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.

Agrahari V, Agrahari V, Mandal A, Pal D, Mitra AK.

Expert Opin Drug Deliv. 2016 Dec 28:1-17. doi: 10.1080/17425247.2017.1272569. [Epub ahead of print]

PMID:
27967247
14.

A comprehensive insight on ocular pharmacokinetics.

Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, Hadji H, Mitra R, Pal D, Mitra AK.

Drug Deliv Transl Res. 2016 Dec;6(6):735-754. Review.

PMID:
27798766
15.

Next generation drug delivery: circulatory cells-mediated nanotherapeutic approaches.

Agrahari V, Agrahari V, Mitra AK.

Expert Opin Drug Deliv. 2017 Mar;14(3):285-289. doi: 10.1080/17425247.2017.1254614. Epub 2016 Nov 22. No abstract available.

PMID:
27791407
16.

Multifunctional thermoresponsive designer peptide hydrogels.

De Leon-Rodriguez LM, Hemar Y, Mo G, Mitra AK, Cornish J, Brimble MA.

Acta Biomater. 2017 Jan 1;47:40-49. doi: 10.1016/j.actbio.2016.10.014. Epub 2016 Oct 12.

PMID:
27744067
17.

Uptake and bioconversion of stereoisomeric dipeptide prodrugs of ganciclovir by nanoparticulate carriers in corneal epithelial cells.

Yang X, Sheng Y, Ray A, Shah SJ, Trinh HM, Pal D, Mitra AK.

Drug Deliv. 2016 Sep;23(7):2532-2540. Epub 2015 Mar 16.

PMID:
25775276
18.

Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir.

Yang X, Shah SJ, Wang Z, Agrahari V, Pal D, Mitra AK.

Drug Deliv. 2016 Sep;23(7):2399-2409. Epub 2015 Jan 7.

PMID:
25564964
19.

Recent perspectives on the delivery of biologics to back of the eye.

Joseph M, Trinh HM, Cholkar K, Pal D, Mitra AK.

Expert Opin Drug Deliv. 2017 May;14(5):631-645. doi: 10.1080/17425247.2016.1227783. Epub 2016 Sep 6. Review.

PMID:
27573097
20.

Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.

Mandal A, Pal D, Mitra AK.

Int J Pharm. 2016 Oct 15;512(1):49-60. doi: 10.1016/j.ijpharm.2016.08.027. Epub 2016 Aug 16.

PMID:
27543355

Supplemental Content

Loading ...
Support Center